- FDA issued a Drug Safety Communication about severe pruritus on discontinuation of cetirizine and levocetirizine.
- Reported cases detail widespread pruritus impacting quality of life and functional capacity.
- Pruritus may recur upon retrying the medications.
- No clear risk factors beyond prolonged use.
- FDA recommends discussing discontinuation risks with patients.
Source: FDA
